Part III in the BHRT Workshop Series


Mastering The Protocols for Optimization of Hormone Therapy

Next Course:

April 29 – May 1, 2022

Upcoming Course Dates

April 29- May 1, 2022 Registration Open

November 4-6, 2022 Registration Opening Soon

Course Description


  1. Part I: Discover the Power of BHRT and
  2. Part II: Expand Treatment Options

The educational process for Part III is both didactic and interactive with maximum audience participation. All of the most complex, interesting, and confusing cases experienced by Dr.Rouzier over the last ten years are presented. The participants decide on the corrective management with literature reviews to guide therapy. Be forewarned, as in the past, many concepts taught in other academies are contrary to the medical literature presented in this course. The attendee will decide therapy based on evidence-based guidelines rather than public opinion. Although there are no medical boards for this type of practice, Part III is similar to a medical board that digs deeper into the complexities of age management medicine.

Clinical cases will be analyzed to formulate appropriate treatments and management to improve the understanding and level of care provided to patients. In Parts I & II the cases and studies are simple and straightforward. However, a thorough understanding of Parts I and II are necessary to understand many of the complex cases presented in Part III. Due to the many different hormones, different studies, different age groups, and misleading and incorrect journalistic conclusions, it is quite difficult for the practitioner to understand and defend their practice of HRT.

Extensive literature summaries that provided credence and support will be presented so that the practitioner has all available data to defend why we do what we do. Studies will be presented that demonstrate more cancer caused by standard statin treatments for cholesterol than by PremPro®. Progesterone causes decreased absorption of estrogen yet it can be anticipated and prevented. Most patients have very low Vitamin D levels (which are harmful), yet most doctors don’t know how to optimally treat and monitor. Differentiation between adrenal hyperplasia and PCOS is important, as well as understanding treatment of thin women vs. obese women and how it will affect future morbidity. It is also important to understand when women require transdermal vs. oral estrogen. The risk of prostate cancer decreases for every doubling of estradiol level or SHBG level, in spite of some academies preaching the need to lower estrogen and SHBG. Also contrary to EBM, these same academies teach the use of progesterone to protect the prostate whereas the evidence demonstrates a potential increase in prostate cancer by progesterone administration to men. Finally, estrogen’s effect on lipids and SHBG are what is most protective against CVD which is provided only by oral estrogen and not transdermal. Each of these topics will be thoroughly addressed.

This course is offered as in-person and via live stream, choose your preference during the registration process.  We will also post the recording each evening for that day.  The recording will be available till Thursday of the week after the event to re-watch or catch anything you may have missed.  It will NOT be available after this time.

Course Objectives

Upon completion of this workshop the health care professional will be able to:

  1. Discuss the most current literature for bio-identical hormone replacement therapy (BHRT), thyroid, testosterone, DHEA, estrogen and progesterone.
  2. Determine the risks and benefits of transdermal estrogen vs. oral estrogen, why one vs. the other one, and review the statistics that claim HRT increases blood clots, or does it?
  3. Examine current policy statements for hormone replacement therapy by the North American Menopause Society (NAMS) and American College of Obstetricians and Gynecologists (ACOG), with a critique and review of their recommendations.
  4. Describe rational approaches for the use of progesterone in treating PMS and PPD.
  5. Discuss new therapies for prostate cancer as well as better diagnostic sensitivity and specificity of MRI-S scan in addition to treatment rationale for prostate cancer survivors through case presentations and literature review.
  6. Determine current management strategies for preventing loss of pregnancy in Polycystic Ovary Syndrome (PCOS) as well as improving pregnancy rates with aromatase inhibitors and the importance of maintaining low levels of aldosterone with PCOS.
  7. Examine literature reviews as to what level of Vitamin D helps protect against cancer, CAD, osteoporosis, dementia, type II DM and AMD as well as how to treat Vitamin D deficiency and how much is too much.
  8. Discuss the pathophysiology of vaginal atrophy and the use of rings, tabs, troches, creams, and DHEA.
  9. Discuss the importance of sex hormone binding globulin (SHBG) in men and women and why it is predictive of CAD, MS and cancer.
  10. Describe the data demonstrating that androgen suppression therapy, as well as estrogen deprivation, is associated with poor survival in men in comparison with placebo.
  11. Describe the difference in clotting between Premarin®, Provera®, esterified estradiol, and micronized progesterone as per JAMA.
  12. Recognize the data demonstrating that only certain types of estrogen increase the production of fatty acid esters that result in protection against atherosclerosis and plaque deposition at the blood vessel wall.
  13. Identify the inverse relationship between estrogen and prostate cancer and the two mechanisms by which estrogen treats and protects against prostate cancer.
  14. Demonstrate skills in multiple case studies with interactive discussion to ensure interpretation and treatment protocols are as demonstrated in our evidenced based scientific literature.
  15. Examine the medical literature to understand how hormones affect cardiovascular disease for both men and women and how Testosterone can both increase and decrease CVD in women by interpreting the correct approach.
  16. In addition to the clinical skills learned in this course group discussions contribute to the collaborative nature of pharmacists working with physicians and nurse practitioners and their patients to determine a personalized approach to prescribing HT. This collaborative provides a continuum of care for patients in ensuring improved patient outcomes and consistency in care


Neal Rouzier, MD

Faculty Chairman

Neal Rouzier, MD

Dr. Neal Rouzier is a pioneer in the bio identical hormone replacement field, practicing almost since its inception in the early 1990’s. He has dedicated his life’s work to uncovering the medical literature that supports safe and effective protocols for unique and personalized patient care. He is the Director of the Preventive Medicine Clinics of the Desert, specializing in the medical management of aging and preventive care for men and women. He has treated more than 2,000 patients with natural hormone replacement therapy and is recognized as a renowned leader and expert in the field. Additionally, Dr. Rouzier is the author of Natural Hormone Replacement for Men and Women: How to Achieve Healthy Aging. He has over 16 years of experience as an educator and practicing physician, and 29 years of Emergency Medicine experience at Queen of the Valley Hospital in West Covina, CA.



7:30 – 8:00 AM – Registration

8:00 AM – 9:00 AM

Section A

Vitamin D: Recent relevant literature review of a most important hormone. Everything that you could possibly want to know about vitamin D

  • Vitamin D3: Diagnosing, prescribing, monitoring, adjusting, and optimizing
  • How much is too much or not enough? Experts disagree on what is optimal
  • How much is toxic per the literature, and what are the symptoms of toxicity
  • Dosing based on serum levels, NTX, and DEXA results
  • Lab review of baseline levels and treatment endpoints

Speakers: Neal Rouzier

 9:00 AM – 10:00 AM

 Section B

  • Diagnosis of PCOS vs. adrenal hyperplasia (21-hydroxylase deficiency) and use of 17α-hydroxyprogesterone to make the diagnosis
  • What the books don’t tell you about complex cases of PCOS
  • PCOS- adverse outcomes and prevention of CAD and cancer
  • Weight loss in PCOS through administration of metformin and thyroid per the literature
  • NAFLD, endothelial dysfunction, aldosterone, & aromatase inhibitors in treating PCOS
  • Focus on the vagina and the various methods to treat and protect against urogenital atrophy
  • Systemic vs. non-systemic absorption of vaginal estrogen
  • Perimenopause = No Man’s Land! Treatment options
  • Doctor, I’m bleeding!!! What to do?  Simply follow the protocol
  • A lab review with treatment guidelines for perimenopause
  • Functional hypothyroidism and receptor site resistance
  • Thyroid does not cause osteoporosis
  • Thyroid in the treatment of heart disease and dyslipidemia

Speakers: Neal Rouzier

10:00 AM – 10:15 AM


 10:15 AM – 12:15 PM

Section 1

  • 50 Case Studies with Q & A

 Speakers: Neal Rouzier

 12:15 PM – 1:15 PM


 1:15 PM – 2:15 PM

Section C

  • The unifying hypothesis of estrogen’s effects on atherosclerosis progression, complications, and plaque vulnerability
  • MMP, clotting factors, inflammatory proteins, and estradiol fatty acid esters in CAD
  • Loss of estrogen associated with increased mortality and dementia
  • The difference in early, mid, and late estrogen replacement
  • The pharmaceutical-company push to block estrogen and the resultant harm of estrogen deprivation- “A Time For Reflection of Aromatase Inhibitors” from Menopause
  • Going against the ACOG guidelines in order to save lives-the literature proves them wrong. All hormones are not the same, so don’t ignore this information
  • The documented benefits of estrogen and the morbidity of loss of estrogen that is ignored
  • A literature review to make sense of the misunderstanding for HRT. Mastering the literature will make you the expert amongst your peers that don’t understand HRT

Speakers: Neal Rouzier

2:15 PM – 4:00 PM

Section 2

  • 50 Case Studies with Question and Answer

Speakers: Neal Rouzier

4:00 PM – 4:15 PM


 4:15 PM – 5:00 PM

Section D

  • A historical perspective to determine why everyone preaches only transdermal estrogen
  • A literature review proving transdermal estrogen is the safest estrogen
  • A literature review proving oral estrogen is the best for saving lives
  • Natural progesterone confers no risk of breast cancer or VTE
  • What about JAMA, EPAT, CORA, WEST, KEEPS, & DANISH trials of oral E2? Why the NIH uses oral E2 and not transdermal
  • Understanding relative risks as your guide for HRT replacement
  • The anti-proliferative, oncostatic, immune stimulatory, and thrombopoetic effects of HRT
  • What you should know about the literature before you speak out

Speakers: Neal Rouzier

5:00 PM – 6:00 PM

Section 3

  • 50 Case Studies with Question and Answer

Speakers: Neal Rouzier


8:00 AM – 9:00 AM

 Section E

  • Importance of optimizing androgens in women for health and well-being
  • Measurement of FAI and implications
  • Does testosterone causes diabetes and breast cancer in women as per the literature
  • SHBG drives the benefit of HRT and is the most important biological marker to predict CAD, MS, and cancer
  • A literature review showing it’s not the testosterone but rather insulin resistance that is the culprit
  • Association does not prove causation
  • SHBG: The most important biological marker to predict DM, CAD, and breast cancer in both men and women
  • It’s not testosterone’s fault but rather the SHBG, or lack thereof that is to blame
  • How and why to safely and successfully raise SHBG

Speakers: Neal Rouzier

9:00 AM – 11:00 AM

 Section 4

  • 50 Case Studies with Question and Answer

Speakers: Neal Rouzier

 11:00 AM – 12:00 Noon

 Section F

  • Testosterone, SHBG, and diabetes in men
  • Testosterone protects against IR→DM→CAD→MS→Cancer
  • Low SHBG predicts all-cause mortality, CAD, osteoporosis, and cancer in men
  • Prostate cancer prevention by SHBG and testosterone
  • The harm of ADT and how to reverse the complications of ADT
  • Testosterone deprivation without estrogen deprivation
  • Lab review of testosterone
  • Sex hormones in men. A literature review demonstrating optimal levels of estrogen and testosterone are necessary for men’s health
  • The harm of blocking estrogen with aromatase inhibitors
  • The benefit of prescribing estrogen in men

Speakers: Neal Rouzier

 LUNCH 12:00 PM – 1:00 PM

1:00 PM – 3:00 PM

Section 5

  • 50 Case Studies with Question and Answer

Speakers: Neal Rouzier

 BREAK 3:00 PM – 3:15 PM

3:15 PM – 4:15 PM

 Section G

  • Safety and efficacy of testosterone in prostate cancer survivors
  • Incidence of prostate cancer and whether we should be treating men with testosterone
  • Why testosterone has become incorrectly and inappropriately associated with prostate cancer
  • All studies refute the prevailing wisdom that testosterone causes prostate cancer
  • The lower the testosterone, the greater the risk of cancer = a paradigm shift
  • Does or will testosterone protect against prostate cancer
  • Dispelling the myths that testosterone and DHT cause prostate cancer. Proving Huggins wrong
  • Peer literature review providing assurance and safety for prescribing testosterone in prostate cancer survivors
  • Surgery vs. radiation vs. HIFU vs. cryotherapy vs. laser ablation for prostate cancer

 Speakers: Neal Rouzier

 4:15 PM – 6:00 PM

Section 6

  • 50 Case Studies with Question and Answer

Speakers: Neal Rouzier


 8:00 AM – 9:00 AM

  Section H

Proof, or lack thereof, that estrogen causes prostate cancer, or at least it does in rats

  • Epidemiologic review of sex hormones and cancer
  • The higher the estradiol, the lower the risk of cancer
  • Collaborative analysis of 18 prospective studies of hormones and cancer
  • ADT increases mortality in men with prostate cancer
  • How to prevent the increased morbidity & mortality, CAD, and side effects of ADT
  • Estrogen’s vasculoprotective effects in men
  • It’s low estrogen that causes osteoporosis, not low testosterone
  • Treatment and prevention of prostate cancer with estrogen
  • Treatment of prevention of cardiovascular disease with estrogen
  • Reversal of ADT side effects with estrogen
  • Estrogen possesses both anti-angiogenic and pro-apoptotic effects not seen with LHRH- agonists
  • The harm of estrogen blockers in men = same harmful effects as estrogen deprivation in women but these are in men

Speakers: Neal Rouzier

9:00 AM – 10:00 AM

Section 7

  • 50 Case Studies with Question and Answer

Speakers: Neal Rouzier

 BREAK 10:00 AM – 10:15 AM

10:15 AM – 11:15 AM

  Section I

  • Postmenopausal HRT in clinical perspective with other standard treatments- a complex literature review of risk vs. benefit in comparison with other standard, commonly used medications
  • The harm of statins and ASA versus the benefit of HRT: What are we thinking
  • Use the scientific literature to guide our therapy
  • Oral P4 reduces serum levels of estradiol whereas transmucosal does not
  • Oral P4 reduces weight, transmucosal does not

 Speakers: Neal Rouzier

Section J

  • Functional hypothyroidism and receptor site resistance vs. resistance from mainstream medicine
  • Thyroid update, thyroid resistance, osteoporosis and cardiovascular disease
  • Progesterone in treatment of PMS, perimenopause, and post-partum depression
  • Treating and monitoring of endometrial proliferation
  • 5α-reductase inhibitors, depression, and sexual dysfunction
  • Progesterone’s role in inflammation, cytokines, and promoting prostate cancer development = the opposite of what you have been misled to believe

Speakers: Neal Rouzier

11:00 AM – 12:00 PM

 Section 8, 9, 10:  HRT pearls, tricks, important points to know about HRT.

Complex Cases with Q & A

 Section K: Complex Lab Review. Strange and unusual cases and labs that make no sense

Wrap-up/ Evaluation/ Q & A/Adjournment


AMA PRA Category 1 Statement

​This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Foundation for Care Management (FCM) and Worldlink Medical. The Foundation for Care Management is accredited by the ACCME to provide continuing medical education for physicians.

FCM designates this educational activity for a maximum of 21 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in this activity.
The ACCME defines a “Commercial Interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Nursing Statement 

Foundation for Care Management is accredited as a provider of nursing continuing professional development

by the American Nurses Credentialing Center’s Commission on Accreditation.

Pharmacy Statement

 The Foundation for Care Management is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program # 0347-9999-20-003-L01-P Objectives appropriate for pharmacists. This activity is 21 Contact Hours Pharmacy Credit.  *This CME is Knowledge Based (K). Initial release May 1, 2020

  • The Foundation for Care Management cannot provide a statement of credit unless an evaluation form has been filled out online. Please go to to access the evaluation form.

Location & Travel Details

Travel Details


Salt Lake City International Airport (SLC)

555 S Main St
Salt Lake City, UT 84111
(801) 258-6000


Click here to book your room.